DE60120928D1 - Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung - Google Patents

Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung

Info

Publication number
DE60120928D1
DE60120928D1 DE60120928T DE60120928T DE60120928D1 DE 60120928 D1 DE60120928 D1 DE 60120928D1 DE 60120928 T DE60120928 T DE 60120928T DE 60120928 T DE60120928 T DE 60120928T DE 60120928 D1 DE60120928 D1 DE 60120928D1
Authority
DE
Germany
Prior art keywords
agents
cephalotaxine
hydroxy
host
cephalotaxinalkaloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60120928T
Other languages
English (en)
Other versions
DE60120928T2 (de
Inventor
M Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ChemGenex Pharmaceuticals Inc
Original Assignee
ChemGenex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ChemGenex Pharmaceuticals Inc filed Critical ChemGenex Pharmaceuticals Inc
Publication of DE60120928D1 publication Critical patent/DE60120928D1/de
Application granted granted Critical
Publication of DE60120928T2 publication Critical patent/DE60120928T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60120928T 2000-03-15 2001-03-15 Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung Expired - Lifetime DE60120928T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18969900P 2000-03-15 2000-03-15
US189699P 2000-03-15
PCT/US2001/008480 WO2001068098A2 (en) 2000-03-15 2001-03-15 Cephalotaxine alkaloid combination compositions and uses thereof

Publications (2)

Publication Number Publication Date
DE60120928D1 true DE60120928D1 (de) 2006-08-03
DE60120928T2 DE60120928T2 (de) 2007-02-08

Family

ID=22698410

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60120928T Expired - Lifetime DE60120928T2 (de) 2000-03-15 2001-03-15 Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung

Country Status (12)

Country Link
US (4) US6734178B2 (de)
EP (1) EP1263440B1 (de)
JP (1) JP4929436B2 (de)
AT (1) ATE330611T1 (de)
AU (2) AU4580301A (de)
CA (1) CA2402710A1 (de)
DE (1) DE60120928T2 (de)
DK (1) DK1263440T3 (de)
ES (1) ES2267741T3 (de)
HK (1) HK1052138A1 (de)
PT (1) PT1263440E (de)
WO (1) WO2001068098A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2402710A1 (en) * 2000-03-15 2001-09-20 Chemgenex Therapeutics, Inc. Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease
US7135481B2 (en) 2000-04-12 2006-11-14 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
US20060211648A1 (en) * 2000-04-12 2006-09-21 Chemgenex Pharmaceuticals, Inc. Naphthalimide compositions and uses thereof
ES2248312T3 (es) 2000-04-12 2006-03-16 Chemgenex Pharmaceuticals, Inc. Composiciones que contienen una naftalmida y un agente aniproliferativo.
US20050170015A1 (en) * 2000-10-31 2005-08-04 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
EP1330242A2 (de) * 2000-10-31 2003-07-30 Chemgenex Therapeutics Inc. Colchicine enthaltende antiproliferative zusammensetzungen und deren verwendung
ATE361746T1 (de) * 2002-03-06 2007-06-15 Medical Res And Education Trus Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
JP2006501199A (ja) 2002-07-17 2006-01-12 ケムジェネックス・ファーマシューティカルズ・リミテッド ホモハリングトニンを含むセファロタキシンの製剤および投与方法
EP1539179B1 (de) * 2002-07-22 2016-03-02 Teva Pharmaceuticals International GmbH Angiogenesehemmung durch cephalotaxin-alkaloide, derivate, zusammensetzungen und ihre verwendungen
CN100396286C (zh) * 2002-12-30 2008-06-25 北京大学第一医院 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用
US20050288310A1 (en) * 2004-06-04 2005-12-29 Chemgenex Pharmaceuticals, Inc. Methods of treating cellular proliferative disease using naphthalimide and PARP-1 inhibitors
EP1848391A2 (de) * 2005-02-10 2007-10-31 ChemGenex Pharmaceuticals, Inc. Medizinische vorrichtungen
CN101677951A (zh) * 2007-04-13 2010-03-24 化学基因制药公司 三尖杉碱口服剂型
EP2260041A4 (de) * 2008-03-03 2012-04-25 Sloan Kettering Inst Cancer Cephalotaxus-ester, verfahren zu ihrer synthese und verwendungen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4675318A (en) * 1985-05-28 1987-06-23 Yaguang Liu Safe antileukemia drug, SAL
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
CA2402710A1 (en) * 2000-03-15 2001-09-20 Chemgenex Therapeutics, Inc. Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease
ES2248312T3 (es) * 2000-04-12 2006-03-16 Chemgenex Pharmaceuticals, Inc. Composiciones que contienen una naftalmida y un agente aniproliferativo.

Also Published As

Publication number Publication date
US20020032190A1 (en) 2002-03-14
JP4929436B2 (ja) 2012-05-09
HK1052138A1 (en) 2003-09-05
ATE330611T1 (de) 2006-07-15
AU2001245803B2 (en) 2005-12-15
AU2001245803B8 (en) 2006-02-02
US20040185117A1 (en) 2004-09-23
PT1263440E (pt) 2006-11-30
EP1263440A2 (de) 2002-12-11
US20110008307A1 (en) 2011-01-13
WO2001068098A2 (en) 2001-09-20
CA2402710A1 (en) 2001-09-20
AU4580301A (en) 2001-09-24
US20120207855A1 (en) 2012-08-16
ES2267741T3 (es) 2007-03-16
EP1263440B1 (de) 2006-06-21
DE60120928T2 (de) 2007-02-08
US6734178B2 (en) 2004-05-11
DK1263440T3 (da) 2006-10-23
WO2001068098A3 (en) 2002-06-06
JP2003526667A (ja) 2003-09-09

Similar Documents

Publication Publication Date Title
DE60120928D1 (de) Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung
ATE309224T1 (de) Pyrimidin-2,4,6-trionen und deren verwendung als metalloproteinase inhibitoren
ES2136137T3 (es) Controles internos para reacciones de amplificacion isotermica de acidos nucleicos.
NO20031852L (no) Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
NO985376D0 (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
TR200201058T2 (tr) P38 protein kinaz inhibitörleri olarak, alkilaminoyla ornatılmış bisiklik, azotlu heterosikller
WO2000072799A3 (en) Method and compositions for treating the inflammatory response
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
TR200003461T2 (tr) Adenosin A3 Alıcı Modülatörleri
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
ATE305312T1 (de) Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten
ATE178939T1 (de) Dna methyltransferase inhibierung
BR0114576A (pt) Composto, composição farmacêutica, uso de um composto, método de tratar um estado doentio e processo para preparar um composto
ATE375358T1 (de) Antiproliferative aktivität von g-reichen oligonukleotiden und verfahren um sie zur bindung an nukleotin zu verwenden
IL131447A0 (en) Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms
AR030741A1 (es) Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
TR199802649A2 (xx) Sikline ba�l� kinazlar�n inhibit�rleri i�in ba�lama e�leri.
NO954880L (no) Cytidin deaminase
EA200000798A1 (ru) Лечение фолликулярных лимфом с использованием ингибиторов каскада реакций лимфотоксина (lt)
WO2001091740A3 (en) Compositions containing naphthaquinone and an antiproliferative agent
ATE243210T1 (de) Aminosäurederivate und deren verwendung als inhibitoren von nep, ace und ece
TR200201252T2 (tr) 15-Hidroksieikosatetraenoik asit ile ilişkili bileşikler ve bunların kullanım yöntemleri
DE69739167D1 (de) Zusammensetzungen zur modulierung der länge von telomeren
TR200201251T2 (tr) Omega zinciri tadil edilmiş 15-hidroksieikosatetraenoik asit türevleri ve bunların göz kurumasının iyileştirilmesi için kullanım yöntemleri

Legal Events

Date Code Title Description
8364 No opposition during term of opposition